53 reports

MARKET ##.

  • Cholesterol
  • APAC
  • Japan
  • United States
  • World

Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: LDL Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Italy: LDL Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Japan: LDL

  • Cholesterol
  • France
  • Japan
  • United States
  • Forecast

Cholesterol Direct Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: LDL Cholesterol Direct Test Volume and Diagnostics Sales Forecasts by Market Segment Italy: LDL Cholesterol Direct Test Volume and Diagnostics Sales Forecasts by Market Segment Japan:

  • Cholesterol
  • France
  • Japan
  • United States
  • Forecast

Cholesterol Test Volume and Sales Forecasts 2021: US, Europe, Japan--Hospitals, Commercial Labs, POC Locations List of Tables France: Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: Cholesterol Test Volume and Diagnostics Sales Forecasts

  • Cholesterol
  • Chronic Disease
  • Japan
  • United States
  • Forecast

HDL Cholesterol Test Volume and Sales Forecasts 2021: US, Europe, Japan--Hospitals, Commercial Labs, POC Locations List of Tables France: HDL Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: HDL Cholesterol Test Volume and Diagnostics Sale

  • Cholesterol
  • Diagnostics
  • Japan
  • United States
  • Forecast
  • POC Cholesterol Testing
  • POC Cholesterol Self-Testing

Point of Care (POC) Cholesterol Testing Market analyzes the market for cholesterol testing performed at or near the site where the patient is located. The report examines the following components of the POC cholesterol market: Global POC Cholesterol Testing Market Analysis, 2012-2020 POC Cholesterol Self-Testing Market Analysis,...

  • Cholesterol
  • Abaxis, Inc.
  • Alere Inc.
  • PTS DIAGNOSTICS
  • Roche Group
  • CHOLESTEROL ABSORPTION INHIBITORS
  • GLOBAL CHOLESTEROL ABSORPTION INHIBITORS MARKET 2016-2021 ($ MILLIONS)

About Dyslipidemia Drugs Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density...

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Statins
  • AstraZeneca PLC
  • Cholesterol and cardiovascular risk
  • Evidence for cholesterol-lowering effects of sterols and stanols

Summary The unambiguous association between cholesterol levels and cardiovascular risk provides a compelling mandate for the development of cholesterol-lowering foods. This report presents the rationale for the use of plant stanol and sterols in lowering blood cholesterol, examines the current market, considers future growth potential,...

  • Cholesterol
  • World
  • Danone SA
  • Raisio Group
  • Unilever PLC

Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Germany: Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Italy: Cholesterol Test Volume and Diagnostics Sales Forecasts by Market Segment Japan: Cholesterol Test Vo

  • Cholesterol
  • France
  • Germany
  • Italy
  • Forecast
  • PRESENTS THE CHOLESTEROL SYNTHESIS PATHWAY, HIGHLIGHTING THE MECHANISM OF ACTION OF STATINS.
  • DYSLIPIDEMIA: FREDRICKSON CLASSIFICATION SYSTEM

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching...

  • Cholesterol
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • Growing demand from emerging markets
  • Global beta-sitosterol market

About Phytosterols Phytosterols are a group of naturally occurring sterol compounds found in plant cell membranes. These substances are important constituents of the plant cell membrane. Phytosterols are of two forms: sterols and stanols. Sterols are the free forms and are commonly found. Stanols are the esterified form of phytosterols;...

  • Cholesterol
  • World
  • Forecast
  • Archer Daniels Midland Company
  • Cargill Inc.
  • Risk Factors and Comorbidities for Dyslipidemia
  • Executive Summary

Plos One; ##(##): ##-##.

  • Cholesterol
  • China
  • Germany
  • United States
  • Forecast

MARKET ##.

  • Cholesterol
  • APAC
  • United States
  • World
  • Company Financials
  • CHOLESTEROL TESTING SERVICES MARKET
  • CHOLESTEROL TESTING/CHOLESTEROL SCREENING SERVICES MARKET, BY TYPE OF CUSTOMER

The global cholesterol testing services market is expected to reach USD 17.5 billion by 2021 from USD 11.9 billion in 2016, growing at a CAGR of 8% during the forecast period. This market is segmented on the basis of type of customer and region. Based on type of customer, the market is segmented into physicians/providers and hospitals; employers,...

  • Cholesterol
  • North America
  • United States
  • Market Size
  • OPKO Health, Inc.

The others segment encompasses market analysis of combination drug therapies such as Advicor, Vytorin, and Caduet, as well as cholesterol inhibitor drugs.

  • Cholesterol
  • Therapy
  • United States
  • Company Financials
  • Market Size
  • 07.2 MECHANISM OF ACTION
  • 07.3 CLINICAL APPLICATION

About Statin Statin is a structural analog of HMG-CoA enzyme and is effective in reducing LDL. It shows its pharmaceutical action by inhibiting the key enzyme involved in cholesterol synthesis, which is called HMG-CoA reductase. Therefore, statin is referred to HMG-CoA reductase inhibitors. Statin has been associated with a beneficial effect...

  • Cholesterol
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • SUMMARIZES THE LEADING BRANDED DRUGS USED TO TREAT DYSLIPIDEMIA.
  • LEADING TREATMENTS FOR DYSLIPIDEMIA, 2014

Dyslipidemia - 5EU Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over...

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • NOV 13, 2014: GALMED PHARMACEUTICALS ANNOUNCES FIRST ADMINISTRATION OF ARAMCHOL IN ITS PHASE IIA TRIAL FOR THE TREATMENT OF CHOLESTEROL GALLSTONES
  • Aramchol - Drug Profile

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP...

  • Cholesterol
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.
  • Jun 04, 2014: Recently Published Independent Research Supports the Importance of Reverse Cholesterol Transport on NASH Pathogenesis
  • Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP...

  • Cholesterol
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.
  • LEADING TREATMENTS FOR DYSLIPIDEMIA, 2014
  • SUMMARIZES THE LEADING BRANDED DRUGS USED TO TREAT DYSLIPIDEMIA.

Dyslipidemia - US Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the...

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • LEADING TREATMENTS FOR DYSLIPIDEMIA, 2014
  • SUMMARIZES THE LEADING BRANDED DRUGS USED TO TREAT DYSLIPIDEMIA.

Dyslipidemia - China Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over...

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • LEADING TREATMENTS FOR DYSLIPIDEMIA, 2014
  • SUMMARIZES THE LEADING BRANDED DRUGS USED TO TREAT DYSLIPIDEMIA.

Dyslipidemia - Japan Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over...

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 5.4.3 DRUGS INCLUDED IN EACH THERAPEUTIC CLASS
  • 4.3.13 MERCK & CO.

Dyslipidemia - Current and Future Players Summary GlobalData has released its pharma report, “Dyslipidemia - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Dyslipidemia Market. The report identifies and analyses the key...

  • Cholesterol
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • There was a significant increase in cholesterol efflux in dalcetrapib-treated AA population, but not the GG genotype
  • JUL 18, 2016: DALCOR DALCETRAPIB DEMONSTRATES GENOTYPE-DEPENDENT EFFECTS ON CHOLESTEROL EFFLUX AND INFLAMMATION IN DATA PUBLISHED BY THE MONTREAL HEART INSTITUTE IN CIRCULATION: CARDIOVASCULAR GENETICS

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H1 2018 Summary According to the recently published report ’Cholesteryl Ester Transfer Protein - Pipeline Review, H1 2018’; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target...

  • Cardiology
  • Cardiovascular Disease
  • Cholesterol
  • Therapy
  • Pfizer Inc.
  • DEC 19, 2016: CAPSTONE THERAPEUTICS ANNOUNCES PROFOUND, RAPID LDL CHOLESTEROL REDUCTION IN AEM-28-14 PRIMATE STUDY
  • 02/21/2017: UAB DEVELOPING NEW PEPTIDE TO COMBAT A DISORDER THAT CAUSES HEART ATTACKS AT EARLY AGE

Summary LipimetiX Development Inc (LipimetiX), formerly LipimetiX LLC is a biopharmaceutical company that develops of drugs for the treatment of refractory hypercholesterolemia and hypertriglyceridemia. The company develops drugs based on chimeric peptide mimetics of apolipoprotein E, a critical protein that directs cholesterol...

  • Cholesterol
  • Therapy
  • United States
  • Deals & Alliance
  • LipimetiX Development LLC
  • Nov 03, 2009: FDA Turns Down Merck's Application For Combo Cholesterol Pill Involving Lipitor
  • Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns

Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H1 2016’, provides in depth analysis on Niemann Pick C1 Like Protein 1 (NPC1L1) targeted pipeline therapeutics. The report provides comprehensive information...

  • Cholesterol
  • South Korea
  • United States
  • World
  • Product Initiative
  • Nov 03, 2009: FDA Turns Down Merck's Application For Combo Cholesterol Pill Involving Lipitor
  • Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns

Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H2 2016’, provides in depth analysis on Niemann Pick C1 Like Protein 1 (NPC1L1) targeted pipeline therapeutics. The report provides comprehensive information...

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • CHOLESTEROL POP TEST - PRODUCT DESCRIPTION
  • CHOLESTEROL POP TEST - PRODUCT STATUS

Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData’s Medical Devices sector report, “Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Clinical Chemistry...

  • Cholesterol
  • Clinical Trial
  • Diagnostics
  • United States
  • GlobalData's company
  • CSL LIMITED
  • adverse cardiovascular event (MACE) defined as cardiovascular death, myocardial infarction (MI), ischemic stroke and hospitalization for unstable angina.

Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016’, provides in depth analysis on Apolipoprotein A I (APOA1) targeted pipeline therapeutics. The report provides comprehensive information on the Apolipoprotein A I (APOA1)...

  • Cholesterol
  • Therapy
  • World
  • Product Initiative
  • Cerenis
  • THERE WAS A SIGNIFICANT INCREASE IN CHOLESTEROL EFFLUX IN DALCETRAPIB-TREATED AA POPULATION, BUT NOT THE GG GENOTYPE
  • BESIDES REQUIRING FREQUENT INJECTIONS, PCSK9 ANTIBODIES WILL LIKELY BE EXPENSIVE AND HAVE NOT SHOWN ANY BENEFICIAL EFFECT ON CHOLESTEROL EFFLUX."

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2017 Summary According to the recently published report ’Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2017’; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close...

  • Cardiovascular Disease
  • Cholesterol
  • Hospital
  • Therapy
  • Pfizer Inc.